There was a reason for Aubagio approval delay after initial CHMP positive opinion. Aubagio was given positive opinion by CHMP initially in March, but without new active substance (NAS) designation because it is a revamped old drug. SNY appealed, CHMP reversed previous opinion by giving Aubagio NAS in June. So you should count from June rather than March.
Market Data 
Markets 
AI
